Skip to main content
Fig. 2 | Genome Medicine

Fig. 2

From: A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis

Fig. 2

Clinical characterization of patients in the discovery cohort. a Proportion of relapsing and non-relapsing patients across bins in the discovery cohort. b Clinical characterization of patients within each bin in the discovery cohorts. Panels a and b show descriptive summaries of clinical characteristics relevant to disease progression across five patient bins. These bins were constructed using the logistic regression model which predicted the probability of being relapse-free conditional on the four SNPs. In a, each tick on the x-axis corresponds to a bin based on a quintile of the predicted probability from the logistic regression model and is labeled with the lowest and the highest predicted probability for the bin. As we move from left to right along the x-axis, the predicted probability of being relapse-free (or being a responder) increases. In each bar, the observed percentages of non-responders and responders are shown using two colors. For a good model, the predicted probabilities should be close to the observed percentages. The figure confirms that this is indeed the case for the logistic regression model. The bars in the graph in a and the columns of the table in b are lined up to show the one-to-one correspondence between the graph and the table. Panel b illustrates that the trends of several alternative clinical response definitions which were not used to construct the four-SNP model align well with the predicted probabilities from the four-SNP model. This suggests that the predictive value of the four-SNP genotype extends beyond the clinical response definitions used to build it. T1 lesions are gadolinium-enhancing T1-weighted lesions on MRI; T2 lesions are T2-weighted MRI lesions. ARR annualized relapse rate, NEDA3 no evidence of disease activity (version 3), NEDA4 no evidence of disease activity (version 4). Percentages of patients meeting the NEDA3 and NEDA4 definitions are shown. The discovery cohorts consisted of the patients from GALA DB and FORTE DB

Back to article page